



- ❖ J. Su et al. ABCB1 C3435T Polymorphism and Response to Clopidogrel Treatment in Coronary Artery Disease (CAD) Patients: A Meta-Analysis. PLOS ONE, 2012.
- ❖ JA Johnson et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for *CYP2C9* and *VKORC1* Genotypes and Warfarin Dosing. Clinical pharmacology & Therapeutics, 2011.
- ❖ K. A Ross et al. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. Journal of Human Genetics, 2010.
- ❖ A. R. Shuldiner ET AL. Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy. JAMA, 2009.
- ❖ F. Takeuchi et al. A Genome-Wide Association Study Confirms *VKORC1*, *CYP2C9*, and *CYP4F2* as Principal Genetic Determinants of Warfarin Dose. PLOS Genetics, 2009.
- ❖ M. D. Crosier et al. Association of Sequence Variations in Vitamin K Epoxide Reductase and γ -Glutamyl Carboxylase Genes with Biochemical Measures of Vitamin K Status. J Nutr Sci Vitaminol, 2009.
- ❖ P. Borgiani et al. *CYP4F2* Genetic Variant (rs2108622) Significantly Contributes to Warfarin Dosing Variability in the Italian Population. Pharmacogenomics, 2009.